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Abstract
CtIP/RBBP8 is a multifunctional protein involved in transcription, DNA repli-
cation, DNA repair by homologous recombination and the G1 and G2 check-
points. Its multiple roles are controlled by its interaction with several specific
factors, including the tumor suppressor proteins BRCA1 and retinoblastoma.
Both its functions and interactors point to a putative oncogenic potential of
CtIP/RBBP8 loss. However, CtIP/RBBP8 relevance in breast tumor appearance,
development, and prognosis has yet to be established. We performed a retro-
spective analysis of CtIP/RBBP8 and RB1 levels by immunohistochemistry using
384 paraffin-embedded breast cancer biopsies obtained during tumor removal
surgery. We have observed that low or no expression of CtIP/RBBP8 correlates
with high-grade breast cancer and with nodal metastasis. Reduction on CtIP/
RBBP8 is most common in hormone receptor (HR)-negative, HER2-positive,
and basal-like tumors. We observed lower levels of RB1 on those tumors with
reduced CtIP/RBBP8 levels. On luminal tumors, decreased but not absence of
CtIP/RBBP8 levels correlate with increased disease-free survival when treated
with a combination of hormone, radio, and chemo therapies.
Introduction
Cancer appearance, development, and progression are
characterized by a progressive accumulation of genetic
mutations that abolish the natural constrains of cellular
division in pluricellular organisms [1, 2]. While in normal
cells mutations build up slowly due to the existence of
multiple mechanisms that prevent them, DNA mutations
at accelerated rates in precancerous and cancer cells accu-
mulate, a phenomenon known as genomic instability [1,
2]. There are many reasons why the genome of cancer
cells is less stable. First, they tend to replicate more and
faster than normal cells, mainly due to the loss of cell
cycle proteins, such retinoblastoma (RB1), that control
the G1/S transition [1, 3, 4]. Second, replication tends to
be more mutagenic in those cells, either due to problems
in the replication machinery itself or in the response to
replication-borne DNA lesions [2, 5]. Third, cancer and
precancer cells usually deal erroneously with damaged
DNA, either not signaling the lesions correctly (e.g., due
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to the lack of p53, RB1, ataxia telangiectasia mutated
(ATM), ataxia telangiectasia and Rad3 related (ATR),
etc.), or due to alterations on the DNA repair mecha-
nisms (caused by mutations such as BRCA1, BRCA2, and
RAD51) [6, 7]. Finally, a more tenuous source of geno-
mic instability is the general upheaval of transcription
profiles in cancer cells, which contribute to increased
mutations [8]. Considering all, it is not surprising that
mutations that affect any of the aforementioned mecha-
nisms of replication, repair, and transcription are usually
selected early on in cancer development and have a net
contribution of cancer progression.
A protein with a strong but not completely explored
cancer connection is CtIP/RBBP8. This protein has been
implicated in several nuclear pathways, mainly through its
interaction with additional factors, many of them bona
fide tumor suppressor genes. CtIP/RBBP8 was first
described as a transcriptional corepressor together with
CtBP [9]. It has also been shown to bind several other
cancer-related transcription factors such as Ikaros, TRB3,
or LMO4 [10–12]. At the same time, CtIP/RBBP8 was
described to play a critical role in the initiation of
S-phase and DNA replication as a negative regulator of
RB1 and the G1 checkpoint [13, 14]. Later, CtIP/RBBP8
was found to participate in DNA replication by binding
proliferating nuclear cell antigen (PCNA) and to play an
important role in minimizing replication-induced DNA
breaks [15]. Finally, CtIP/RBBP8 plays a critical role in
DNA damage detection, signaling, and repair, mainly by
its interactions with BRCA1 and the MRE11-RAD50-
NBS1 (MRN) complex [16–18].
Despite these connections with cancer, little is known
about the role of CtIP/RBBP8 as a tumor suppressor gene
itself. CtIP/RBBP8 microsatellite-induced frameshift
mutations have been found in colorectal cancer [19, 20]
and endometrial cancer [21], and point mutations have
been observed in some cancer cell lines [18]. Strikingly,
haploid insufficiency in mouse led to increased tumor
appearances, of mainly large B cell lymphomas [13].
Functionally, CtIP/RBBP8 transcriptional activity seems
to contribute to cancer development and treatment
success [22–24]. In addition, CtIP/RBBP8 is a key player
in cell cycle control, through its interaction with RB1, as
its activity is required for overcoming RB1-mediated cell
cycle arrest [13, 14]. The relationship between both fac-
tors is so tight that CtIP/RBBP8 knock-out in mouse is
lethal in the presence of functional RB1 [13].
The stronger link between CtIP/RBBP8 and cancer,
and specifically breast cancer, relies in its functional
interaction with BRCA1 in DNA repair. CtIP/RBBP8 and
BRCA1 physically interact and act together in the
homologous recombination pathway [17, 18, 25, 26]. In
fact, BRCA1 point mutations that abolish its interaction
with CtIP/RBBP8 have been associated with tumor
progression [27–29]. In stark contrast, other mutations in
conserved BRCA1 regions that maintain CtIP/RBBP8 bind-
ing are considered benign [30]. Despite this relationship,
no CtIP/RBBP8 mutations have been observed so far in
families with hereditary cancer but that are wild type for
BRCA1 and BRCA2 [31]. However, an association with
specific CtIP/RBBP8 haplotypes has been proposed to be a
cancer-risk modifier in breast cancer for BRCA1 mutation
carriers [32], but not for ovarian cancer [32, 33].
Despite all the available data, no systematic study of
CtIP/RBBP8 expression on breast cancer samples and its
correlation with treatment response and disease-free
survival has been done. We have now performed this
study using 384 paraffin-embedded breast cancer biopsies
obtained during tumor removal surgery between 2004
and 2007 at a single institution. We have analyzed CtIP/
RBBP8 and RB1 presence on all tumor samples and cor-
related their expression levels with cancer prognosis
markers. We observed a significant link between CtIP/
RBBP8 and RB1 expression, as well as a strong relation-
ship between CtIP/RBBP8 levels and specific breast cancer
types. From this, we conclude that patients with luminal
cancer who have decreased CtIP/RBBP8 expression
respond better to the combined hormone therapy, radio-
therapy, and chemotherapy treatment than patients with
normal or no CtIP/RBBP8 expression.
Patients and Methods
Patients and tissue sampling
A total of 384 formalin-fixed paraffin-embedded (FFPE)
samples of invasive breast carcinomas were obtained from
patients diagnosed from July 2004 to July 2007 at Univer-
sity Hospital Virgen del Rocıo, Sevilla, Spain. The Ethical
Committee of the Hospital approved the study. No con-
sent from the patients was needed.
All biopsies were stained with anti-CtIP/RBBP8 and
anti-RB1 antibodies, but not all samples could be
included for every correlations made in this study due to
the absence of data related to tumoral classification or
disease-free survival after the treatment.
Clinicopathologic data, including age, local and distant
metastasis, regional lymph node metastasis, histologic
grade, tumor size, tumoral markers, treatment and sur-
vival, were obtained from medical records (Table 1).
Three of the patients included in this study were men;
the male tissue samples were considered in the same way
as the female samples. The median age was 63 years
(range, 27–91 years). The mean follow-up period was
67 months (median, 78 months; range, 1–106 months).
Nine samples corresponded to relapsed breast tumors, and
ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 775
I. Soria-Bretones et al. CtIP/RBBP8 Expression in Breast Cancer
these cases were not included in the disease-free survival
study. Similarly, patients were treated with chemotherapy
before surgery was excluded from the correlations.
Immunohistochemical staining and scoring
Paraffin-embedded tissue cores (1 mm) were used to
build four tissue microarrays, each containing 96 samples
that were sectioned at 4 lm. Immunohistochemical stain-
ing was carried out to visualize the CtIP/RBBP8- and
RB1-positive cells. Paraffin sections were dewaxed in
xylene and rehydrated through a graded ethanol series.
Antigen retrieval for CtIP/RBBP8 staining was performed
with 4N HCl at room temperature for 15 min, followed
by 1 mg/mL trypsin at 37°C for 15 min. RB1 samples
were heated in Target retrieval solution, pH 9 (Dako,
Glostrup, Denmark), using a microwave at 600 W for
20 min. Tissue sections were subsequently immersed in
3% H2O2 aqueous solution for 30 min to exhaust endog-
enous peroxidase activity, and then covered with blocking
reagent (Roche, Mannheim, Germany) to avoid nonspe-
cific binding. Tissue sections were incubated with primary
antibodies overnight at 4°C, using CtIP/RBBP8 mouse
monoclonal antibody 1:50 (R. Baer, Columbia University,
New York, NY) and RB1 rabbit polyclonal antibody 1:750
(ab39689; Abcam plc, Cambridge, U.K.). Peroxidase-
labeled secondary reagents and 3,3′-diaminobenzidine
were applied according to the manufacturer’s protocols
(EnVisionTM FLEX for RB1 and EnVisionTM FLEX Mouse
[Linker] for CtIP/RBBP8, Dako). Slides were then count-
erstained with hematoxylin and mounted in DPX (BDH
Laboratories, Poole, U.K.). Immunostaining was evaluated
independently by two observers and scored as follows:
CtIP/RBBP8 0, no nuclear staining; 1, moderate; 2,
strong; RB1 0, no nuclear staining; 1, intermediate
nuclear staining; and 2, strong nuclear staining.
Statistical analysis
The association between CtIP/RBBP8 expression and clini-
copathological features was examined by the chi-square test.
Disease-free survival curves were calculated by the Kaplan–
Meier method. Survival curves were compared by the log-
rank test of Mantel and Haenszel. Calculations were
performed using Prism 5.0 (GraphPad, San Diego, CA).
Breast cancer subtyping according to
estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth
factor receptor-2 (HER2) status
The breast tumor samples were classified into five sub-
types of luminal A (ER+ and/or PR+, HER2 and Ki-67
Table 1. Patient description.
n = 384 %
Tumor
T1 136 35.4
T2 160 41.7
T3 32 8.3
T4 11 2.9
n.d. 45 11.7
Node
Negative 165 43.0
Positive 157 40.9
Unknown 62 16.1
Grade
1 41 10.7
2 140 36.5
3 178 46.4
n.d. 25 6.5
ER
Negative 91 23.7
Positive 267 69.5
n.d. 26 6.8
PR
Negative 135 35.2
Positive 223 58.1
n.d. 26 6.8
HER2
Negative 300 78.1
Positive 65 16.9
n.d. 19 4.9
Ki67
Negative 77 20.1
Positive 243 63.3
n.d. 64 16.7
Phenotype
Luminal A 70 18.2
Luminal B HER2 145 37.8
Luminal B HER2+ 23 6
HER2+ (nonluminal) 33 8.6
Triple negative 52 13.5
Unknown 61 15.9
Treatment
Adjuvant (300) 78.1
Chemotherapy 183
Hormonal 230
Radiotherapy 202
Anti-HER2 32
Neoadjuvant (17) 4.4
Chemotherapy 15
Hormonal 2
Radiotherapy 1
Anti-HER2 1
No treatment 13 3.4
Unknown 54 14.1
Gender
Female 381 99.2
Male 3 0.8
ER, estrogen receptor; PR, progesterone receptor; HER2, human
epidermal growth factor receptor-2.
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low), luminal B HER2 negative (ER+ and/or PR+,
HER2 and Ki-67 high), luminal B HER2 positive (ER+
and/or PR+, HER2 overexpressed or amplified, and any
Ki-67), HER2 positive (nonluminal) (HER2 overexpressed
or amplified, ER and PR), and triple negative (ER,
PR, and HER2), according to the system for the
immunohistochemical subtyping of breast cancer [34].
Results
To analyze a potential CtIP/RBBP8 relationship with
breast cancer clinicopathological variables, we analyzed
384 biopsies obtained during tumor removal surgery
between 2004 and 2007 at the University Hospital Vir-
gen del Rocıo, Sevilla, Spain. Three of the patients were
men (Table 1). The age of the patients range from 27 to
91, with a median of 63. All the clinicopathological vari-
ants studied are described in Table 1. More than 77% of
the samples corresponded to low stage (T1 or T2), and
over 70% were hormone receptor (HR) positive. Only
17% were positive for HER2, 62% were luminal cancers,
and only 13.5% were triple negative. Grade 3 tumors
(49.6%) were more represented than grade 2 (39%) or
grade 1 (11.4%). The proliferation marker Ki67 was
present in 63.3% of the samples. A summary of the dif-
ferent treatments the patients received is also shown in
Table 1.
We performed an immunohistochemistry study of the
CtIP/RBBP8 levels in the paraffin-embedded samples
(Fig. 1). We detected three different CtIP/RBBP8 levels
(Fig. 1): level 0 contained samples in which no CtIP/
RBBP8 could be detected with the antibody; level 1 repre-
sented an intermediate level; and level 2 corresponded to
samples with a clear nuclear signal of CtIP/RBBP8 in
more than 90% of the cells of the tumor. The specificity
of the antibody for immunostaining was previously
showed [26] and can be observed in Figure S1. Based on
mRNA studies, it has been proposed that CtIP/RBBP8
might be overexpressed in certain cancers [12, 35], hence
it was important to unequivocally determine which of the
three levels corresponded to basal, nonpathological CtIP/
RBBP8 protein expression. We thus used six nontumors
samples from breast reduction surgery to establish the
normal CtIP/RBBP8 expression level on healthy mam-
mary glands (Figs. 1 and S2). For these, we observed that
a strong nuclear staining was readily observed in ductal
cells in all cases, despite some variations within samples.
Based on this, we concluded than normal tissue has an
expression level equivalent to level 2. Thus, we considered
all samples with a level 2 expression of CtIP/RBBP8 to be
normal, and those with level 1 to represent downregula-
tion of the protein. Level 0 corresponded to a complete
lack of CtIP/RBBP8. Importantly, we did not find any
tumor sample that overexpressed CtIP/RBBP8 in the
cohort.
After characterizing all samples for their CtIP/RBBP8
levels, we analyzed the correlation with the clinicopatho-
logical variations listed in Table 1. We found that CtIP/
RBBP8 expression affects all the given parameters in a
statistically significant way (Table 2). Lower levels of
CtIP/RBBP8 correlated with more aggressive and
advanced clinical characteristics and usually corresponded
to grade 3 tumors that had a higher probability to present
node metastasis and were less likely to be at the T1 stage.
Figure 1. CtIP/RBBP8 and retinoblastoma (RB1) expression in breast cancer biopsies. Paraffin-embedded breast cancer biopsies were
immunostained with CtIP/RBBP8 or RB1 antibodies and stained with hematoxylin and eosin as described in the Patients and Methods section. A
representative image of each cancer subtype is shown. In addition, the gradation of CtIP/RBBP8 and RB1 protein level can be observed from 2
(normal; left) to 0 (triple negative; right).
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Normal CtIP/RBBP8 level cancers are usually grade 2, at
a lower stage (T1), and less likely to present node metas-
tasis. Whereas we found a strong bias for tumors with
normal CtIP/RBBP8 levels to be positive for ER and PR
receptors (of 91.5% and 78%, respectively), breast cancers
with no CtIP/RBBP8 staining had an almost equal distri-
bution of HR-positive and HR-negative samples. In addi-
tion, the proportion of HER2+ tumors was significantly
higher in tumors expressing low or no CtIP/RBBP8.
Moreover, the lower the level of detected CtIP/RBBP8,
the higher the proliferation of the cells (as measured by
the presence of Ki67).
Surprisingly, we found 40% of the samples had no
detectable CtIP/RBBP8 expression. CtIP/RBBP8 is an
essential gene in mammals [13] unless RB1 expression is
also diminished [13]. Thus, we reasoned that the tumor
samples without CtIP/RBBP8 expression might correlate
with an altered expression of RB1. Lack of RB1 in many
tumors has been widely proven [3], and breast cancer is
not an exception [36–38]. Thus, we decided to analyze
the presence of RB1 in the same breast samples we tested
for CtIP/RBBP8 levels, to see if there was a correlation
between their expression (Fig. 1 and Table 3). We
detected three distinct cell types with respect to RB1
expression: samples with high nuclear RB1 levels, similar
to noncancer samples from breast reduction surgery
(Fig. S2); samples with no expression; and samples with a
reduced RB1 expression. Analyzing all the cancer biopsies
for RB1 and CtIP/RBBP8 patterns revealed a strong statis-
tically significant correlation between RB1 and CtIP/
RBBP8 (Table 3): in more than 90% of those samples in
which CtIP/RBBP8 was absent, RB1 was also either absent
or reduced. However, more than half of the samples with
normal CtIP/RBBP8 expression also retained high RB1
expression levels. An intermediate situation was observed
on the samples that had been determined to have low
CtIP/RBBP8 levels.
As our data link CtIP/RBBP8 loss with more advanced
and aggressive tumors, we next statistically analyzed the
relationship between CtIP/RBBP8 expression levels and
disease-free survival for patients for whom full clinical
follow-ups were available (Figs. 2 and 3). First, we ana-
lyzed CtIP/RBBP8 levels at the time of biopsy and the
interval of time during which the patients remained dis-
ease free; this revealed that there was no significant corre-
lation between in tumor relapse and CtIP/RBBP8 protein
levels (Fig. 2A). We then focused on luminal tumors, for
which the CtIP/RBBP8 expression levels were evenly dis-
tributed between normal, low, and absence. It was previ-
ously reported that CtIP/RBBP8 silencing could be a
mechanism of tamoxifen resistance [24]. We therefore
analyzed the effects on CtIP/RBBP8 levels at the time of
the biopsy in response to tamoxifen in luminal breast
tumors. Patients in the studied cohort have been treated
with either tamoxifen, aromatase inhibitors, or a combi-
nation of both. Analyzing these three groups indepen-
dently, we observed no differences in disease-free survival,
Table 2. CtIP/RBBP8 expression in breast cancer and its relationship
with clinicopathological variables.
Absence Low Normal P-value
Tumor
T1 46 (33.3) 51 (45.5) 36 (50.0) 0.032
T2 71 (51.4) 43 (38.4) 34 (47.2)
T3 16 (11.6) 13 (11.6) 1 (1.4)
T4 5 (3.6) 5 (4.5) 1 (1.4)
Node
Negative 69 (47.9) 52 (47.3) 44 (64.7) 0.044
Positive 75 (52.1) 58 (52.7) 24 (35.3)
Grade
1 9 (5.8) 15 (12.2) 17 (20.7) <0.0001
2 53 (34.4) 42 (34.1) 45 (54.9)
3 92 (59.7) 66 (53.7) 20 (24.4)
ER
Negative 64 (41.8) 20 (16.3) 7 (8.5) <0.0001
Positive 89 (58.2) 103 (83.7) 75 (91.5)
PR
Negative 75 (49.3) 42 (33.9) 18 (22) 0.0001
Positive 77 (50.7) 82 (66.1) 64 (78)
HER2
Negative 123 (77.8) 102 (81) 75 (92.6) 0.017
Positive 35 (22.2) 24 (19) 6 (7.4)
Ki67
Negative 23 (16.1) 31 (29.0) 23 (32.9) 0.009
Positive 120 (83.9) 76 (71) 47 (67.1)
Phenotype
Luminal A 22 (15.7) 27 (23.9) 21 (30) <0.0001
Luminal B HER2 53 (37.9) 51 (45.1) 41 (58.6)
Luminal B HER2+ 7 (5) 15 (13.3) 1 (1.4)
HER2+ 22 (15.7) 6 (5.3) 5 (7.1)
Triple negative 36 (25.7) 14 (12.4) 2 (2.9)
ER, estrogen receptor; PR, progesterone receptor; HER2, human epi-
dermal growth factor receptor-2. Absolute number of biopsies
assigned to each clinicopathological subtype and CtIP/RBBP8 expres-
sion level. The number in brackets represents the percentage of sam-
ples within a given category of CtIP/RBBP8 expression.
Table 3. Correlation between CtIP/RBBP8 and RB1 expression in
breast cancer biopsies.
Absence Low Normal P-value
Retinoblastoma
Normal 9 (6.4) 27 (23.9) 41 (54.7) <0.0001
Intermediate 88 (62.9) 72 (63.7) 32 (42.7)
Negative 43 (30.7) 14 (12.4) 2 (2.7)
Absolute number of biopsies assigned to each RB1 level and CtIP/
RBBP8 expression level. The number in brackets represents the per-
centage of samples within a given category of CtIP/RBBP8 expression.
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independent of the CtIP/RBBP8 levels in the three groups
(Fig. 2B–D). All patients in the study with luminal
tumors were treated with hormone therapy and radio-
therapy. However, we could distinguish two groups
depending on whether or not chemotherapy was used as
an adjuvant. Thus, when we analyzed the disease-free
interval on those categories, we observed that patients
without a chemotherapeutical treatment responded in a
similar way irrespectively of the CtIP/RBBP8 levels
(Fig. 3A). However, a statistically significant correlation
was observed for patients who were treated with chemo-
therapy as an adjuvant (Fig. 3B). Strikingly, low expres-
sion of CtIP/RBBP8 correlated with a lower proportion of
tumor relapse as compared to patients with normal CtIP/
(A) (B)
(C) (D)
Figure 2. Disease-free survival and response to hormone therapy of patients in the cohort with respect to the CtIP/RBBP8 levels. (A) Overall
representation of tumor relapse in all the patients of the cohort. Disease-free survival data were obtained from clinical records and plotted using
the Kaplan–Meier method. The cohort was divided according to CtIP/RBBP8 levels as follows: level 2, normal expression (black line, n = 66); level
1, low expression (blue line, n = 102); level 0, no expression (red line, n = 128). (B) Kaplan–Meier representation of the time patients with luminal
tumors treated with tamoxifen remained disease free. CtIP/RBBP8 levels: level 2, normal expression (black line, n = 10); level 1, low expression
(blue line, n = 13); level 0, no expression (red line, n = 20). (C) Disease-free survival times in patients with luminal tumors treated with aromatase
inhibitors. CtIP/RBBP8 levels: level 2, normal expression (black line, n = 25); level 1, low expression (blue line, n = 22); level 0, no expression (red
line, n = 23). (D) Tumor relapse in patients with luminal tumors treated with a combination of tamoxifen and aromatase inhibitors. CtIP/RBBP8
levels: level 2, normal expression (black line, n = 14); level 1, low expression (blue line, n = 18); level 0, no expression (red line, n = 13).
(A) (B)
Figure 3. Relationship between the CtIP/RBBP8 levels and the response to chemotherapy for luminal cancers. (A) Disease-free survival times in
patients with luminal tumors not treated with chemotherapy. CtIP/RBBP8 levels: level 2, normal expression (black line, n = 14); level 1, low
expression (blue line, n = 12); level 0, no expression, (red line, n = 14). (B) Tumor relapse in patients with luminal tumors treated with
chemotherapy as an adjuvant. An asterisk represents statistically representative changes (P < 0.05). CtIP/RBBP8 levels: level 2, normal expression
(black line, n = 20); level 1, low expression (blue line, n = 18); level 0, no expression (red line, n = 21). In both cases (A and B), patients were
treated with radiotherapy and hormone therapy.
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RBBP8 levels (P < 0.05). A similar (but not statistically
significant) trend was observed for samples with low
CtIP/RBBP8 as compared to those in which the protein
was absent. No differences were observed between tumors
with normal CtIP/RBBP8 expression and those in which
the protein was absent (nt).
Discussion
CtIP/RBBP8 is a protein with a strong connection to can-
cer due to its functional and physical interactions with
bona fide tumor suppressors. Although some studies have
found CtIP/RBBP8 to be mutated in tumor samples [18–
21], and some general screenings using RT-polymerase
chain reaction (PCR) have found changes in its mRNA
levels (Oncomine), we describe here the first systematic
study of the presence of CtIP/RBBP8 at the protein level.
We performed a retrospective study to correlate CtIP/
RBBP8 expression with clinicopathological variables and
disease-free survival. We found that the CtIP/RBBP8 level
is indeed relevant in the appearance and prognosis of
breast cancer. Thus, we propose that CtIP/RBBP8 itself
should be considered as a tumor suppressor.
In agreement with our results, genome-wide screen-
ings that analyzed CtIP/RBBP8 expression in different
tumors at the level of mRNA using microarrays [24, 39–
43] have also reported a correlation between high CtIP/
RBBP8 expression and a positive ER mark. However,
even though CtIP/RBBP8 mRNA was found to be over-
represented in certain tumors [12, 35], we have never
observed overexpression at the protein level in breast
cancer.
CtIP/RBBP8 overexpression was first identified in
tumors linked with an increase of cyclin D1 transcrip-
tion [35]. A different report also described CtIP/RBBP8
increases, which were, however, not significant [12].
Although we cannot discard that CtIP/RBBP8 protein
levels are indeed increased in some samples, our data
suggest that its contribution to cancer development is
mainly due to its loss. CtIP/RBBP8 protein and mRNA
expression are tightly controlled at many different levels,
including gene transcription and protein degradation
during the cell cycle [13, 35, 44–46]. Moreover, several
protein modifications are involved in protein stability.
Thus, mRNA expression does not always correlate with
protein expression, and extrapolating CtIP/RBBP8 levels
from mRNA data could be misleading. In fact, it is pos-
sible that this previously reported mRNA overexpression
represents an attempt to increase protein levels that are
abnormally low due to increased protein degradation.
Wu et al. [24] found that low levels of CtIP/RBBP8 at
the time of diagnosis protect cancer cells from tamoxifen
treatment. This observation prompted them to propose
CtIP/RBBP8 silencing as a novel mechanism for tamoxi-
fen resistance in breast cancer. They analyzed the response
to tamoxifen of 59 nonoperable ER+ breast tumors and
found that the lower the expression of CtIP/RBBP8, the
lower the tumor size reduction. However, they did not
study tumor relapse in the long term. In the cohort stud-
ied here, no differences to the response of hormone treat-
ment were observed, for example, not from tamoxifen,
aromatase inhibitors, or a combination of both, in terms
of long-term disease-free survival. Therefore, we propose
that breast cancers with low levels of CtIP/RBBP8 might
respond worse to tamoxifen treatment, but that once
those tumors were resected, the probability of tumor
relapse for those patients treated with tamoxifen was the
same, irrespective of the level of CtIP/RBBP8 expression
detected in the biopsy.
Strikingly, when we analyzed the response of luminal
cancers to a coadjuvant treatment with chemotherapy, we
discovered that patients with low levels of CtIP/RBBP8
responded better (Fig. 3B). All 18 of those patients
remain disease free for as long as the study took place.
Therefore, although lower CtIP/RBBP8 expression corre-
lated with more aggressive tumors at the time of diagno-
sis, treatment is more effective in this specific subset.
Most chemotherapeutic agents used as coadjuvant base
their action in artificially creating DNA damage, either
directly or by increasing replication stress [47]. CtIP/
RBBP8 is an important player in the response to DNA
damage; indeed, CtIP/RBBP8 depletion renders cells
sensitive to those agents, such as camptothecin or VP16
[16]. Thus, we conclude that cells with reduced overall
levels of CtIP/RBBP8 are responding better to the che-
motherapy due to this increased sensitivity. In fact, we
propose that studying CtIP/RBBP8 expression could be
used as a marker to define which cancers should be trea-
ted with chemotherapeutic agents. Surprisingly, this
sensitivity is partially lost in cells that do not express any
CtIP/RBBP8, and patients with no CtIP/RBBP8 expres-
sion behave intermediately between those classified in
low and normal CtIP/RBBP8 levels. There can be several
alternative explanations for this finding. First, it is possi-
ble that the total absence of CtIP/RBBP8 activates alter-
native DNA repair pathways that can (at least partially)
handle the DNA damage caused by these therapeutical
agents. Second, although RB1 is reduced in those cancers
without CtIP/RBBP8, it is likely that the cell cycle pro-
gression is affected. As many of the chemotherapeuticals
act during S-phase, it would not be surprising that the
amount of DNA lesions created is greatly reduced for can-
cers without CtIP/RBBP8, rendering the drugs less effective.
Finally, the intermediate trend observed for tumors in
which CtIP/RBBP8 is absent could reflect the small num-
bers of biopsies analyzed (n = 21). It is possible that a lar-
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ger study would find that patients with no CtIP/RBBP8
expression are also more sensitive to chemotherapy.
In conclusion, we have performed a retrospective study
of the relationships between CtIP/RBBP8 expression levels
and cancer prognosis and relapse using paraffin-embedded
breast cancer biopsies from a cohort of 384 patients. Our
results suggest a strong relationship between no or low
expression of CtIP/RBBP8 and poor breast cancer progno-
sis. On the other hand, CtIP/RBBP8 is a poor marker for
predicting the overall response to treatment and cancer and
disease-free survival. However, low levels of CtIP/RBBP8
increase the response to chemotherapy in luminal cancers
when combined with hormone therapy and radiotherapy.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. CtIP/RBBP8 antibody specificity for immuno-
staining. U2OS cells were transfected with a previously
characterized siRNA against CtIP/RBBP8 (siCtIP) or a
control siRNA (siCtrl) [16] and immunostained with
anti-CtIP antibody.
Figure S2. CtIP/RBBP8 expression in normal mammary
gland. (A) Paraffin-embedded normal breast tissue was
immunostained with CtIP/RBBP8 antibody and hematox-
ylin as described in the Patients and Methods section. (B)
A representative image of each CtIP and RB expression
category is shown for comparison. From left to right cate-
gories 2, 1, and 0 (normal, low, or no expression of CtIP/
RBBP8 and RB1). Compare nuclear staining with (A).
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